Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genchain Biotech
Suzhou, Jiangsu, Chinagenchainbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Genchain Biosciences is a clinical-stage biotechnology company specializing in the development of next-generation gene therapies. Based in Suzhou, China, the company leverages its proprietary AAV (Adeno-associated virus) platform to create treatments for rare genetic disorders. Its lead program, GC101, is an AAV-based gene therapy for Hemophilia B that has entered clinical trials. Genchain also maintains a robust pipeline targeting metabolic and neuromuscular diseases, including Pompe disease and Fabry disease. The company is backed by prominent venture capital firms such as Qiming Venture Partners and IDG Capital.
- Therapeutic areas
- HematologyRare Diseases
- Modalities
- Gene therapyAAV vector
- Industry
- Biotech
Beyond the preview
Go deeper on Genchain Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genchain Biotech.